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SUMMAry – Background: Cervical lymph node metastases are frequently found in papillary 
thyroid carcinoma (PtC) and occur in a stepwise fashion. Skip metastases that omit the central com-
partment and spread initially in lateral neck levels are present in a certain share of patients, and their 
significance is poorly understood. The aim of this prospective study was to identify their possible 
predictors and clinicopathological factors in a group of patients with PtC with lateral lymph node 
(lln) metastases. Methods: We enrolled 68 patients with PtC with preoperatively evaluated lln 
metastases who underwent total thyroidectomy with lateral lymph node dissection between 2011 and 
2018. We analysed the clinicopathological features and pattern of dissemination of continuous and 
skip metastases. Results: The prevalence of skip metastases was 23.5%. Compared with the continuous 
metastases group, the patients were older, had primary tumors that were more often situated unilater-
ally, and had smaller primary tumor size. level ii was less often involved, and none of the patients 
with skip metastases had all lnn positive (p = 0.05). Conclusion: Skip metastases occur more fre-
quently in older patients and display certain clinicopathological features like smaller size of the pri-
mary tumor and dissemination in less lateral neck levels. in the view of the fact that they are found 
rather frequently, lateral neck regions should be meticulously investigated in patients with PtC with-
out central lymph node (Cll) metastases.
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Introduction
Cervical lymph node metastases are relatively com-
mon in papillary thyroid cancer (PtC) (1) and occur 
in 30-80% of patients (2). They have a characteristic 
way of disseminating initially in the pretracheal, para-
tracheal, and upper mediastinal lymph nodes (central 
neck lymph nodes, Cln). Afterwards, tumor cells 
spread to ipsilateral neck lymph nodes (lln), levels ii 
to v. Finally, they disseminate in contralateral lymph 
nodes of the neck (3-7). There is also an unconven-
tional pathway in which tumor cells omit the Cll and 
metastases first occur in lln (8,9). This kind of me-
tastases is termed a skip metastasis, and it is hypothe-
sized that they display different clinicopathological 
features compared with continuous metastases (10) 
and therefore have a different prognosis (11). There are 
several studies and meta-analyses in the literature re-
garding PtC skip metastases, but they were either 
performed on a smaller number of patients or larger 
groups from multiple hospitals; some of them with re-
curring patients and/or treated by different surgeons 
(12-14). The aim of our study was to determine the 
general occurrence, predictors, and association of skip 
metastases with certain clinicopathological features in 
a group of patients with primary PtC with proven 
B. Miličić et al. Skip Metastases in Papillary Thyroid Carcinoma
Acta Clin Croat, Vol. 59, (Suppl. 1) 2020 123
lln metastases. our results will provide further in-
sight into management options and altering the treat-
ment according to our findings.
Patients and methods
This prospective study was approved by the local 
institutional review Boards. We enrolled all patients 
with PtC who had lln metastases. The patients 
were surgically treated between 2011 and 2018 at the 
University hospital Centre, department of otolaryn-
gology, head and neck Surgery. All surgeries were 
carried out by the same surgeon. All of the patients 
had previously untreated PtC with lln metastases, 
preoperatively confirmed and evaluated by ultrasonog-
raphy (US) for tumor size, location, and the presence 
of lymph node metastases (lnM). lnM were after-
wards investigated with fine needle aspiration biopsy 
(FnAB). exclusion criteria were prior thyroid surgery 
or radiotherapy, extensive PtC with distant metasta-
ses, or other thyroid malignancy. The patients under-
went total thyroidectomy alongside with Cln and 
lln dissection. levels of the neck were categorized 
according to the American head and neck Society 
(15). Specimens were afterwards subjected to patho-
logical analysis (PA). Skip metastases are defined as 
lateral lymph node metastasis with no positive nodes 
in the central compartment. extracapsular spread re-
fers to spreading beyond the lymph node capsule. All 
results are presented as mean +/- Sd if not stated 
 otherwise.
Ethics
This study was approved by the Zagreb University 
hospital Centre Bioethical Board adhering to the 
helsinki declaration of 2013. All patients have read 
and signed a written consent document. 
Statistics
SPSS version 14 (iBM, Chicago, il, USA) was 
used to perform statistical analysis. Associations be-
tween skip metastases in the lln and several clinico-
pathologic factors were assessed with univariate analy-
ses using the Pearson Chi-square test or the Fishers 
exact test. Continuous variables, such as primary tu-
mor size and number of positive lymph nodes accord-
ing to the presence or absence of skip metastasis were 
evaluated using the t-test. Statistical significance was 
defined as P < 0.05.
Results
Patient demographics
out of 100 patients, 68 met the requirements for 
our study. out of 32 patients that did not meet the 
requirements, 15 underwent surgery prior to the study, 
9 underwent radiotherapy, 7 underwent surgery and 
radiotherapy, and one had an extensive tumor with dis-
tant metastases. Mean age was 36.5 years (range 11-
74) and the male to female ratio was 1:4 (17 vs 51). 
The mean primary tumor size was 2.04 cm (± 1.65, 
range 0.2-7.0 cm); 26.5% percent of tumors were 
smaller than 1 cm in diameter. tumors were mostly 
situated in the right lobe (44.11%) while localization 
in the left lobe was observed in 26.4% of the patients 
and bilateral location in 29.4% of the patients. Multi-
centric growth was found in 73% of the patients.
Mean number of total dissected lateral lymph 
nodes was 33.73 (±17.66, range 10-107), while the 
number of positive nodes was 5.07 (± 4.03, range 
1-19).
level iii was involved most often (79.4%), fol-
lowed by level iv, level ii, and v (table 1). Skip metas-
Table 1. Demographics and clinical characteristics
variables results
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tases were present in 23.5% of patients. There were 8 
patients (11.8%) with false-negative ultrasonography 
finding of the central neck levels prior to pathological 
analysis. 
Prevalence and distribution of skip metastasis  
on the lateral neck
We compared the clinicopathological characteris-
tics of patients with skip and continuous metastases 
(table 2). Patients with skip metastases were signifi-
cantly older (median age: 54 vs 33 years). Skip metas-
tases were more common in men than in women 
(31.25% vs 23.0%).
regarding tumor localization, we did not find a 
significant difference in prevalence of localization in 
either lobe, but the primary tumors with skip metasta-
ses showed a trend of being situated bilaterally less of-
ten (18.75% vs 32.70%). The mean size of primary tu-
mors was smaller in the skip metastases group (1.49 
cm vs 2.21 cm). There was however no significant dif-
ference in microcarcinoma frequency between the two 
groups. The number of harvested lateral lymph nodes 
was similar (32.25% vs 34.20%), but the mean number 
of positive nodes was smaller in the skip group. 
(11.24% skip vs 16.14 % continuous). in contrast to 
the continuous metastases group, lnn in the skip 
metastases group had a smaller proportion of positive 
nodes in each level, especially in level ii (p = 0.006) 
and somewhat in level iii (p = 0.05) (table 2). More-
over, none of the patients in that group had all lln 
levels positive, while 17,3% of patients in the conti-
nuous metastases group had all lln levels positive 
(p = 0.05).
Frequencies of tumors with extrathyroidal growth 
and positive lymph nodes with extracapsular spread of 
metastases were similar in both groups.
Discussion
The thyroid gland has an extensive and rich lym-
phatic drainage which makes predicting metastases 
Table 2. Clinicopathological factors of skip compared with continuous LLN metastases
variables Skip metastases Continuous metastases p value
total (n=68) 23.5% 76.5%
Mean age 54.0±16.7 33 ± 15.26 p = 0.02*
> 45 62.5% 30.7% p = 0.042*
gender (%men) 31.25% men 23% men p = 0.06
localization
left 31.25% 25% p = 0.62
right 50% 42.3% p = 0.68
Bilateral 18.75% 32.7% p = 0.014*
tumor size 1.49 cm ± 0.78 2.211 cm ± 1.81 p = 0.13
Microcarcinoma 31.25% 25% p = 0.620
Multicentric 62.5% 76.9% p = 0.33
extrathyroidal spread 56.25% 53.84% p = 0.86
lateral ln
total 516 (mean 32.25 ± 14.14) 1778 (34.20 ± 18.7) p = 0.7
Metastatic 58 ± (11.24%) 278 ± (16.14%) p = 0.1
Metastatic nodes
level ii 18.75% 57.60% p = 0.006 *
level iii 62.5% 84.60% p = 0.05 *
level iv 62.5% 76.92% p = 0.25
level v 31.25% 30.70% p = 0.97
All levels positive 0.0% 17.30% p 0.05 *
extracapsular (ln) 54.9% 53.84% p = 0.86
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dissemination quite challenging. it is generally accept-
ed that tumor cells spread in a stepwise fashion: ini-
tially into pretracheal, paratracheal, and upper medias-
tinal ln, then into ipsilateral neck lymph nodes, and 
finally to contralateral neck regions (6). Some authors 
even theorized that lymphatic systems of the lobes are 
separated (16), but practice reveals that contralateral 
regional metastases are possible (17). Skip metastases, 
which initially disseminate in the lateral region, are 
not so rare, and they occur in 6.5-27.5% of PtC with 
lln metastases (8,14,18-20). our result (23%) falls 
into the upper end of that range. ito et al. even pro-
posed that continuous spread does not exist and that 
there is an equal chance for continuous and skipping 
dissemination. Their explanation was based on the 
finding that the percentage of solely lln and Cln 
metastases was similar (18.1% vs 22.9%). in another 
study by ito, it was 29.0% vs 33.3% (21,22).
lln metastases in PtC are associated with a 
higher risk of regional recurrence (9,23). re-operation 
increases the risk of intra- and postoperative compli-
cations as well as overall medical costs (3,4,24,25); sur-
geons are therefore confronted with the question 
whether to perform para- and pretracheal dissection in 
patients with present lln metastases and absent 
Cln metastases. The significance of PtC skip metas-
tases is still not fully understood, and their wide range 
of prevalence between different studies could be a re-
sult of studies which were limited by low patient num-
bers and the inclusion of primary and recurrent pa-
tients in their research populations (26).
our results show that the mean number of har-
vested positive lln was smaller in the skip metastases 
group and that there was a tendency of fewer positive 
nodes in each level. Another finding of ours is that 
none of the patients with skip metastases had all lln 
positive, while that was not the case in the continuous 
metastases group. We did not find such data in similar 
studies on PtC with skip metastases, but this can be 
explained by characteristics of PtC skip metastases 
that seem to induce better prognosis (8,14).
According to some theories, PtC skip metastases 
occur when the primary tumor is situated in the upper 
poles of the thyroid gland, where the lymphatic drain-
age follows the pathway of the upper thyroid artery. 
Another possibility is that it spreads per continuitatem 
in the lateral regions (27,28). in our case, it is evident 
that mostly middle and lower lln levels were affect-
ed in the skip group, and especially level ii (and to 
some extent level iii) had significantly fewer positive 
nodes (table 2). This is different from studies which 
stated that skip metastases disseminated more fre-
quently in level ii (14), possibly as a result from the 
aforementioned hypothetic lymphatic drainage situ-
ated around superior thyroid artery (14,29). in all our 
patients, we found skip metastases only in level iia and 
none in level iib. From our results, it is clear that con-
tinuous metastases – as compared with skip metastases 
– disseminate more evenly in all lln levels.
We obtained a similar number of lymph nodes in 
each patient group, therefore excluding the probability 
of false-negative data as a result of inadequate lymph 
node sampling or possible previous surgeries.
Primary tumor size was another clinicopathologi-
cal feature which showed a trend of being smaller in 
the skip group. Similar results can be seen in most of 
the studies in the literature, with the tumor size being 
inversely associated with the probability of skip metas-
tases (11,14,26).
over 70% of all our patients had multifocal tumor 
growth, which is quite a high percentage as compared 
with other studies (30). Multifocality was, however, 
less often present in patients with skip metastases, 
which is to some extent similar to findings by nie et al. 
(11). extracapsular ln spread was another factor in-
versely correlated with skip metastases in a study by 
lim and koo (26), but we did not find significant dif-
ferences between our groups. These facts have led to 
several authors concluding that skip metastases could 
mean better prognosis and could be associated with 
less aggressive forms of PtC (8,11). This would in fact 
be in concordance with skip metastases outcomes in 
other primary tumor localizations such as colorectal or 
small cell lung cancer, where they positively affect sur-
vival rate (31,32).
in the present study, we found a significantly high-
er chance for skip metastases in older patients (62.5% 
vs 32.7%, p = 0.02) who were above 45 years of age. it 
is known that higher age is negatively correlated with 
prognosis in PtC (33,34) and that it does not affect 
the tumor metastasizing potential significantly (35), 
which is contradictory to the previously mentioned 
hypothesis (8,11). on the other hand, studies have also 
shown that there is a smaller chance for continuous 
lln metastases in older patients (36).
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Possible limitations of our study include the lack of 
information on the exact tumor location in the thyroid 
gland. however, we found a smaller proportion of bi-
lateral tumors in the skip metastases group. Some 
studies found localization in upper lobe to be associ-
ated with skip metastases (13,14), but that was also 
demonstrated for increased frequency of continuous 
lnM in other studies (37). Another possible draw-
back is the fact that lateral neck dissection (levels ii-
iv) which we performed was therapeutical rather than 
prophylactic. According to one study, latent lln me-
tastases which were not found preoperatively clinically 
nor with US were found after PA in over 50% of pa-
tients who underwent prophylactic lateral dissection 
(22). Therefore, including such patients might have 
revealed other possible predictive factors.
Conclusion
in summary, our results showed that PtC with 
skip metastases tend to present different clinicopatho-
logical characteristics than PtC with continuous me-
tastases. Primary tumors were often smaller in size, 
displayed bilateral growth less often, and occured more 
frequently in older patients. Moreover, skip metastases 
seem to less frequently metastasize in certain lateral 
neck levels, and they almost never affect all lateral neck 
levels.
All of this implies the need for thorough lateral 
neck regions investigation in patients with PtC who 
do not have central neck levels metastases, bearing in 
mind the aforementioned facts. Further prospective 
studies with a larger number of patients with PtC 
with skip metastases should be undertaken to assess 
the impact on patient outcomes and other possible 
predictive factors.
Author’s note
This study was approved by the University hospital 
Centre Zagreb, Zagreb, Bioethical Board adhering to 
the helsinki declaration of 2013. All of the authors 
have read and approved the manuscript.
Declaration of conflicting interests
The author(s) declare no potential conflicts of in-
terest with respect to the research, authorship, and/or 
publication of this article.
Funding
The author(s) received no financial support for the 
research, authorship, and/or publication of this article.
Abbreviations:
Cll – central lymph nodes
FnAB – fine-needle aspiration biopsy
ln – lymph nodes
lln – lateral lymph nodes
lnM – lateral neck metastases
PtC – papillary thyroid carcinoma
PA – pathological analysis
Sd – standard deviation
US – ultrasonography
References:
 1. Sivanandan r, Soo kC. Pattern of cervical lymph node metas-
tases from papillary carcinoma of the thyroid. Br J Surg. 2001 
Sep;88(9):1241–4.
 2. Ar S. Management of the neck in thyroid cancer. otolaryngol 
Clin north Am. 1998 oct 1;31(5):823–31.
 3. Shaha Ar. editorial: Complications of neck dissection for 
Thyroid Cancer. Ann Surg oncol. 2008 Feb;15(2):397–9.
 4. Wada n, duh Q-y, Sugino k, iwasaki h, kameyama k, 
Mimura t, et al. lymph node metastasis from 259 papillary 
thyroid microcarcinomas: frequency, pattern of occurrence and 
recurrence, and optimal strategy for neck dissection. Ann Surg. 
2003 Mar;237(3):399–407.
 5. radivojević rC, Prgomet d, Markesić J, ezgeta C. hypocal-
caemia after thyroid surgery for differentiated thyroid carcino-
ma: preliminary study report. Coll Antropol. 2012 nov;36 
Suppl 2:73–8.
 6. Machens A, hinze r, Thomusch o, dralle h. Pattern of nodal 
metastasis for primary and reoperative thyroid cancer. World J 
Surg. 2002 Jan;26(1):22–8.
 7. Medicinska naklada. tUMori glAve i vrAtA [internet]. 
[cited 2020 Apr 8]. Available from: https://www.medicins-
kanaklada.hr/tumori-glave-i-vrata
 8. Machens A, holzhausen h-J, dralle h. Skip metastases in 
thyroid cancer leaping the central lymph node compartment. 
Arch Surg Chic ill 1960. 2004 Jan;139(1):43–5.
 9. roh J-l, Park J-y, Park Ci. total thyroidectomy plus neck dis-
section in differentiated papillary thyroid carcinoma patients: 
pattern of nodal metastasis, morbidity, recurrence, and postop-
erative levels of serum parathyroid hormone. Ann Surg. 2007 
Apr;245(4):604–10.
10. So yk, kim M-J, kim S, Son y-i. lateral lymph node metas-
tasis in papillary thyroid carcinoma: A systematic review and 
meta-analysis for prevalence, risk factors, and location. int J 
Surg lond engl. 2018 Feb;50:94–103.
B. Miličić et al. Skip Metastases in Papillary Thyroid Carcinoma
Acta Clin Croat, Vol. 59, (Suppl. 1) 2020 127
11. nie X, tan Z, ge M. Skip metastasis in papillary thyroid carci-
noma is difficult to predict in clinical practice. BMC Cancer. 
2017 oct 25;17(1):702.
12. Chung yS, kim Jy, Bae J-S, Song B-J, kim JS, Jeon hM, et al. 
lateral lymph node metastasis in papillary thyroid carcinoma: 
results of therapeutic lymph node dissection. Thyroid off J Am 
Thyroid Assoc. 2009 Mar;19(3):241–6.
13. lee yS, Shin S-C, lim y-S, lee J-C, Wang S-g, Son S-M, et 
al. tumor location-dependent skip lateral cervical lymph node 
metastasis in papillary thyroid cancer. head neck. 2014 Jun; 
36(6):887–91.
14. Park Jh, lee yS, kim BW, Chang h-S, Park CS. Skip lateral 
neck node metastases in papillary thyroid carcinoma. World J 
Surg. 2012 Apr;36(4):743–7.
15. American Thyroid Association Surgery Working group, 
American Association of endocrine Surgeons, American 
Academy of otolaryngology-head and neck Surgery, Ameri-
can head and neck Society, Carty Se, Cooper dS, et al. Con-
sensus statement on the terminology and classification of cen-
tral neck dissection for thyroid cancer. Thyroid off J Am Thy-
roid Assoc. 2009 nov;19(11):1153–8.
16. Fernandez-Cruz l, Astudillo e, Pera C. lymphography of the 
thyroid gland: is intraglandular dissemination of thyroid carci-
noma possible? World J Surg. 1977 Sep;1(5):647–54.
17. eichhorn W, tabler h, lippold r, lochmann M, Schrecken-
berger M, Bartenstein P. Prognostic factors determining long-
term survival in well-differentiated thyroid cancer: an analysis 
of four hundred eighty-four patients undergoing therapy and 
aftercare at the same institution. Thyroid off J Am Thyroid As-
soc. 2003 oct;13(10):949–58.
18. Bj l, Sg W, Jc l, Sm S, ij k, yk k. level iib lymph node me-
tastasis in neck dissection for papillary thyroid carcinoma. Arch 
otolaryngol head neck Surg. 2007 oct 1;133(10):1028–30.
19. Bumber B, Marjanovic kavanagh M, Jakovcevic A, Sincic n, 
Prstacic r, Prgomet d. role of matrix metalloproteinases and 
their inhibitors in the development of cervical metastases in 
papillary thyroid cancer. Clin otolaryngol off J ent-Uk off 
J neth Soc oto-rhino-laryngol Cervico-Facial Surg. 2020; 
45(1):55–62.
20. klišeska e, Makovac i. Skip Metastases in Papillary Thyroid 
Cancer. Coll Antropol. 2012;36 supplement 2(2):59–62.
21. ito y, tomoda C, Uruno t, takamura y, Miya A, kobayashi k, 
et al. Clinical significance of metastasis to the central compart-
ment from papillary microcarcinoma of the thyroid. World J 
Surg. 2006 Jan;30(1):91–9.
22. ito y, Jikuzono t, higashiyama t, Asahi S, tomoda C, taka-
mura y, et al. Clinical significance of lymph node metastasis of 
thyroid papillary carcinoma located in one lobe. World J Surg. 
2006 oct;30(10):1821–8.
23. Shaha Ar. Prognostic factors in papillary thyroid carcinoma 
and implications of large nodal metastasis. Surgery. 2004 
Feb;135(2):237–9.
24. grabovac S, Prgomet d, Janjanin S, hadzibegović Ad. [Para-
thyroid hormone values in thyroid gland surgeries by harmonic 
scalpel and by conventional methods]. lijec vjesn. 2013 
dec;135(11–12):306–10.
25. Prgomet d, Janjanin S, Bilić M, Prstacić r, kovac l, rudes M, 
et al. A prospective observational study of 363 cases operated 
with three different harmonic scalpels. eur Arch oto-rhino-
laryngol off J eur Fed oto-rhino-laryngol Soc eUFoS 
Affil ger Soc oto-rhino-laryngol - head neck Surg. 2009 
dec;266(12):1965–70.
26. lim yC, koo BS. Predictive factors of skip metastases to lat-
eral neck compartment leaping central neck compartment in 
papillary thyroid carcinoma. oral oncol. 2012 Mar;48(3): 
262–5.
27. ito y, Miyauchi A. lateral lymph node dissection guided by 
preoperative and intraoperative findings in differentiated thy-
roid carcinoma. World J Surg. 2008 May;32(5):729–39.
28. Prgomet d, Bilić M, kovac l, hutinec Z, topić i. [locally 
invasive papillary thyroid cancer--our experience]. lijec vjesn. 
2012 oct;134(9–10):266–70.
29. ito y, tomoda C, Uruno t, takamura y, Miya A, kobayashi k, 
et al. Papillary microcarcinoma of the thyroid: how should it be 
treated? World J Surg. 2004 nov;28(11):1115–21.
30. horvatic herceg g, herceg d, kralik M, kulic A, Bence-Zig-
man Z, tomic-Brzac h, et al. Urokinase plasminogen activator 
and its inhibitor type-1 as prognostic factors in differentiated 
thyroid carcinoma patients. otolaryngol--head neck Surg off 
J Am Acad otolaryngol-head neck Surg. 2013 oct;149(4): 
533–40.
31. Prenzel kl, Mönig SP, Sinning JM, Baldus Se, gutschow CA, 
grass g, et al. role of skip metastasis to mediastinal lymph 
nodes in non-small cell lung cancer. J Surg oncol. 2003 Apr; 
82(4):256–60.
32. yamamoto y, takahashi k, yasuno M, Sakoma t, Mori t. 
Clinicopathological characteristics of skipping lymph node 
metastases in patients with colorectal cancer. Jpn J Clin oncol. 
1998 Jun;28(6):378–82.
33. Cho JS, yoon Jh, Park Mh, Shin Sh, Jegal yJ, lee JS, et al. 
Age and prognosis of papillary thyroid carcinoma: retrospective 
stratification into three groups. J korean Surg Soc. 2012 nov; 
83(5):259–66.
34. Chereau n, trésallet C, noullet S, godiris-Petit g, tissier F, 
leenhardt l, et al. Prognosis of papillary thyroid carcinoma in 
elderly patients after thyroid resection: A retrospective cohort 
analysis. Medicine (Baltimore). 2016 nov;95(47):e5450.
35. Punda A, Bedeković v, Barić A, kontić M, Čolović Z, vanjaka 
rogošić l, et al. ret expression and its correlation with clini-
copathologic data in papillary thyroid carcinoma. Acta Clin 
Croat. 2018 dec;57(4):646–52.
36. Wada n, Masudo k, nakayama h, Suganuma n, Matsuzu k, 
hirakawa S, et al. Clinical outcomes in older or younger pa-
tients with papillary thyroid carcinoma: impact of lymphade-
nopathy and patient age. eur J Surg oncol eJSo. 2008 Feb 
1;34(2):202–7.
37. lin k-l, Wang o-C, Zhang X-h, dai X-X, hu X-Q, Qu 
J-M. The BrAF mutation is predictive of aggressive clinico-
pathological characteristics in papillary thyroid microcarcino-
ma. Ann Surg oncol. 2010 dec;17(12):3294–300.
B. Miličić et al. Skip Metastases in Papillary Thyroid Carcinoma
128 Acta Clin Croat, Vol. 59, (Suppl. 1) 2020
Sažetak
PreSkAČUĆe MetAStAZe PAPilArnog kAriCinoMA ŠtitnJAČe  
– UČeStAloSt, Prediktivni i kliniČko-PAtoloŠki ČiMBeniCi
B. Miličić, R. Prstačić i D. Prgomet
Uvod: Metastaze u limfnim čvorovima vrata čest su nalaz kod papilarnog karcinoma štitnjače i pojavljuju se određenim 
redoslijedom. tzv. „skip“ metastaze koje “preskaču” centralni odjeljak te se šire inicijalno u lateralne regije vrata mogu se naći 
u određenom broju tih pacijenata, a njihov značaj nije još dobro istražen. Cilj ove prospektivne studije jest identificirati nji-
hove moguće prediktore i kliničko-patološke značajke u skupini pacijenata s lateralnim metastazama papilarnog karcinoma 
štitnjače. Metode: U studiju je bilo uključeno 68 pacijenata s papilarnim karcinomom kojima su prethodno verificirane late-
ralne metastaze te su bili podvrgnuti totalnoj tiroidektomiji uz lateralnu disekciju vrata, u razdoblju od 2011 do 2018 godine. 
Analizirane su i uspoređene kliničko-patološke značajke te obrazac metastaziranja kontinuiranih i skip metastaza. Rezultati: 
Učestalost skip metastaza bila je 23,5%. U usporedbi sa skupinom s kontinuiranim metastazama, ti pacijenti bili su stariji, 
primarni tumori bili su rjeđe bilateralni, te su bili manjih dimenzija. regija ii bila je rjeđe zahvaćena, te nitko od tih pacije-
nata nije imao sve regije zahvaćene metastazama. Zaključak: Skip metastaze pojavljuju se češće u starijih pacijenata te poka-
zuju određene kliničko-patološke značajke kao što su manja dimenzija primarnih tumora, te diseminacija u manje lateralnih 
regija vrata. Uzevši u obzir da se takve metastaze relativno često susreću, lateralne regije vrata trebale bi se temeljito istražiti 
u pacijenata s papilarnim karcinomom štitnjače bez metastaza u centralnim odjeljcima vrata. 
ključne riječi: skip metastaze, papilarni karcinom štitnjače, kliničko-patološke značajke, lateralne metastaze vrata
